详情页

当前位置：首页 > 详情页

The Tracking Molecular Evolution for NSCLC (T-MENC) Study

10| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Geneplus-Beijing Co. Ltd. [2]Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 [3]China-Japan Friendship Hospital Beijing, Beijing, China, 100029 [4]Beijing Friendship Hospital, Capital Medical University Beijing, Beijing, China, 100050 [5]Xuanwu Hospital Capital Medical University Beijing, Beijing, China, 100053 [6]Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China, 101149 [7]Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050011 [8]Hebei General Hospital Shijiazhuang, Hebei, China, 050051 [9]Tangshan People's Hospital Tangshan, Hebei, China, 063001 [10]The First Bethune Hospital of Jilin University Changchun, Jilin, China, 130021 [11]Beijing Hospital Beijing, Beijing, China, 100005

研究目的：

Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection. Plasma circulating tumor DNA (ctDNA) analysis detects molecule residual disease and predicts recurrence in patients. The concordance of the relative abundance of mutations in plasma ctDNA with cancer recurrence.